menu
    • menu
    [{"orgOrder":0,"company":"Jixing Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Jixing Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jixing Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Jixing Pharmaceuticals \/ Bayer AG"}]

    Find Clinical Drug Pipeline Developments & Deals by Jixing Pharmaceuticals

    Menu

    Jixing Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jixing Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Jixing Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aficamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Bayer AG

                            Deal Size : $162.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Bayer and RTW Investments Lead Series D in Chinese Biotech Ji Xing Pharmaceuticals

                            Details : The financing will enable the company to support Ji Xing Pharmaceuticals in the commercialization of JIXING’s pipeline assets in the areas of cardiovascular diseases and ophthalmology.

                            Product Name : CK-3773274

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 06, 2024

                            Lead Product(s) : Aficamten

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Bayer AG

                            Deal Size : $162.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth